EGCG

Interactions between crude drug extracts used in Japanese traditional Kampo medicines and organic anion-transporting polypeptide 2B1.

1. J Ethnopharmacol. 2018 Mar 25;214:153-159. doi: 10.1016/j.jep.2017.12.016. Epub 2017 Dec 14. Interactions between crude drug extracts used in Japanese traditional Kampo medicines and organic anion-transporting polypeptide 2B1. Iijima R(1), Watanabe T(1), Ishiuchi K(1), Matsumoto T(2), Watanab

The Role of Dietary Supplements in the Treatment of Endometriosis: A Critical Review.

1. Nutrients. 2026 Apr 17;18(8):1274. doi: 10.3390/nu18081274. The Role of Dietary Supplements in the Treatment of Endometriosis: A Critical Review. Wójtowicz M(1), Małek P(2), Olszanecka-Glinianowicz M(2). Author information: (1)Clinical Department of Gynecology and Obstetrics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-055 Katowice, Poland. (2)Health Promotion and Obesity Management Unit, Department of Pathophysiology, Faculty of Medical Sciences in Katowice, Medical University of Silesia, 40-055 Katowice, Poland. Background: There is a growing number of studies suggesting the effectiveness of dietary supplements in preventing and treating endometriosis. It has been suggested that deficiencies in vitamins D and E as well as zinc are associated with the increased risk of endometriosis development. Beneficial effects of magnesium, curcumin, resveratrol and epigallocatechin-3-gallate were found in experimental animal studies. A reduction in pain related to endometriosis was shown in women using omega-3 and alpha-lipoic acid. Meanwhile, decreasing endometriotic lesion size after the supplementation of omega-3, N-acetylcysteine, vitamin C and epigallocatechin-3-gallate was observed in animal and human studies. Thus, the aim of this critical review was to summarize the available data describing the effects of dietary supplements used in the treatment of endometriosis. Material and Methods: The PubMed, Embase, Cochrane, and Web of Science databases were searched for related studies until 15 December 2025. Finally, 34 studies were included in the synthesis. Results: Of these 34 studies, only 23 were randomized, placebo-controlled trials. There have been no RCTs evaluating the effectiveness of vitamin E, zinc, alpha-LA, EGCG and DIM in the treatment of endometriosis. Single studies evaluating the effectiveness of vitamin C, magnesium, resveratrol, NAC and PEA with PLD have not confirmed it. Meanwhile single studies evaluating the effectiveness of selenium, propolis and quercetin have confirmed it. Of the four studies assessing the effectiveness of vitamin D, two confirmed it and two did not; of the two studies assessing probiotics, one confirmed its effectiveness and one did not; of the two studies assessing curcumin, one confirmed its effectiveness and one did not; and of the three studies assessing omega-3, two confirmed its effectiveness and one did not. All four RCTs assessing the combination of vitamins C and E confirmed their effectiveness. Conclusions: Despite encouraging observations from experimental studies, the results of RCTs are less encouraging and do not allow for the formulation of recommendations concerning the use of supplements in the treatment of endometriosis symptoms according to EBM. DOI: 10.3390/nu18081274 PMID: 42075089 [Indexed for MEDLINE]

Dietary Bioactives in Alzheimer's Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies.

2. Nutrients. 2026 Mar 12;18(6):907. doi: 10.3390/nu18060907. Dietary Bioactives in Alzheimer's Disease: A Critical Appraisal of Clinical Trials and Future Nutritional Strategies. Kumari A(1)(2), Zeng XA(1)(2)(3)(4). Author information: (1)School of Food Science and Engineering, South China University of Technology, Guangzhou 510640, China. (2)Guangdong Key Laboratory of Food Intelligent Manufacturing, Foshan University, Foshan 528225, China. (3)School of Food Science and Engineering, Foshan University, Foshan 528225, China. (4)Overseas Expertise Introduction Centre for Discipline Innovation of Food Nutrition and Human Health (111 Centre), Guangzhou 510640, China. Background: Alzheimer's disease (AD) remains a major public health challenge. Observational associations between dietary patterns and reduced dementia risk have prompted investigations of dietary bioactives (DBs) as cognitive nutraceuticals. Methods: This critical narrative review examines interventional trials for nine prominent DBs relevant to AD: docosahexaenoic acid (DHA), curcumin, resveratrol, epigallocatechin gallate (EGCG), nicotinamide riboside (NR), tricaprilin, vitamin E (α-tocopherol), cannabinoids, and NIC5-15 (D-pinitol). Trials were identified through ClinicalTrials.gov (search date: December 2024) and supplemented by PubMed searches for published results. Data were extracted on trial phase, design, cognitive/functional endpoints, biomarker outcomes, and development status. Findings are synthesized qualitatively; no formal meta-analysis or risk of bias assessment was conducted. Results: None of the nine bioactives demonstrated consistent cognitive efficacy in AD. Phase III trials of DHA, curcumin, and tricaprilin did not meet primary cognitive endpoints. Resveratrol reduced CSF Aβ40 without cognitive benefit. Cannabinoids improved behavioral symptoms but showed no measurable cognitive effects. High-dose vitamin E slowed functional decline, while cognition remained unchanged. In contrast, trials in preclinical or at-risk populations reported preliminary cognitive signals for EGCG and biomarker engagement for NR, suggesting potential for early intervention. Conclusions: Current clinical evidence does not support high-dose DBs supplementation as an effective treatment for AD. Predominantly negative late-phase findings highlight limitations, with potential contributors including limited bioavailability, late intervention, insufficient target engagement, and biological heterogeneity. Future research may benefit from early biomarker-defined populations, optimized formulations, multi-nutrient or dietary approaches, and precision nutrition strategies considering genetic risk and baseline nutrient status. DBs may be better positioned for prevention or early-stage intervention rather than late-stage therapy. DOI: 10.3390/nu18060907 PMCID: PMC13029159 PMID: 41901082 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflicts of interest.

A Randomized Controlled Trial to Determine the Effects of Curcumin and Epigallocatechin-3-Gallate Supplementation on Serum Brain-Derived Neurotrophic Factor and Mood Disturbance in Adults.

3. Nutrients. 2026 Mar 6;18(5):855. doi: 10.3390/nu18050855. A Randomized Controlled Trial to Determine the Effects of Curcumin and Epigallocatechin-3-Gallate Supplementation on Serum Brain-Derived Neurotrophic Factor and Mood Disturbance in Adults. Cavanah AM(1)(2), Robinson LA(1)(2), Aguilar MM(3), Molaison EF(2), Greene MW(2), Roberts MD(3), Fruge AD(1). Author information: (1)College of Nursing, Auburn University, Auburn, AL 36849, USA. (2)Department of Nutritional Sciences, Auburn University, Auburn, AL 36849, USA. (3)School of Kinesiology, Auburn University, Auburn, AL 36849, USA. Background/Objectives: Mood disorders like depression, anxiety, and stress have increased steadily among adults, with growing interest in non-pharmaceutical treatments to improve symptomology. Epigallocatechin-3-gallate (EGCG) and curcumin are polyphenols with evidence to support their positive impacts on mood disorder symptomology and potential mood-associated biomarkers like brain-derived neurotrophic factor (BDNF). This study examined the effects of combined EGCG and curcumin supplementation on mood disturbance symptomology and serum brain-derived neurotrophic factor in adults. Methods: An 8-week randomized double-blinded placebo-controlled trial was conducted in adults (n = 64, 18-50 years old). Participants were randomized to a supplement group (n = 32; 350 mg EGCG and 1330 mg curcumin daily) or a matched placebo group (n = 32). Mood disturbance (DASS-21, GAD-7), sleep disturbance (GSAQ), and physical activity (IPAQ) were assessed at baseline, Week 4, and Week 8. Anthropometric measures, 24 h diet recalls, and fasted blood samples for serum BDNF were collected at baseline and Week 8. A multivariate ANOVA evaluated primary outcomes (DASS-21 composite score and BDNF), followed by repeated measures ANOVA for secondary outcomes (p < 0.05). Results: Significant improvements were observed across all participants for mood (DASS-21 composite and subscales, GAD-7, p < 0.001 for all), sleep (p < 0.001), and physical activity (p < 0.01), with no significant difference between supplement and placebo groups. Mean serum BDNF increased in both groups, but neither were statistically significant with no group-by-time interactions. Sugar intake (g/kg body weight) was positively correlated with mood symptoms at Week 8 in the supplement group. Baseline fruit and vegetable intake was associated with mood symptom severity at select time points; however, dietary changes during the intervention were not significantly related to changes in mood outcomes. Conclusions: Combined EGCG and curcumin supplementation did not show additional benefits beyond placebo for mood disturbance or serum BDNF over eight weeks. Observed improvements across both groups suggest that behavioral or lifestyle factors may play a larger role in short-term mood improvements than supplementation alone. DOI: 10.3390/nu18050855 PMCID: PMC12986582 PMID: 41830024 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflicts of interest.

Effects of Green Tea Extract Supplementation on Inflammatory Cytokines Among Postmenopausal Women with Overweight or Obesity-A Secondary Analysis of a Randomized Controlled Trial.

4. Nutrients. 2026 Jan 1;18(1):143. doi: 10.3390/nu18010143. Effects of Green Tea Extract Supplementation on Inflammatory Cytokines Among Postmenopausal Women with Overweight or Obesity-A Secondary Analysis of a Randomized Controlled Trial. Cunningham A(1), Gomes A(1), Meng L(2), Shapses S(3)(4), Byham-Gray L(1), Samavat H(1). Author information: (1)Department of Clinical and Preventive Nutrition Sciences, School of Health Professions, Rutgers University, Newark, NJ 07102, USA. (2)Department of Internal Medicine, University of Arizona College of Medicine, Phoenix, AZ 85724, USA. (3)Department of Nutritional Sciences, Rutgers University, Newark, NJ 07102, USA. (4)Department of Medicine, Rutgers RWJ Medical School, New Brunswick, NJ 08901, USA. Background: Excess adiposity induces low-grade inflammation, including increased C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). Green tea contains epigallocatechin gallate (EGCG), with anti-inflammatory potential. EGCG metabolism is influenced by individual variations in catechol-O-methyltransferase (COMT) genotypes. Objectives: To evaluate the effect of green tea extract (GTE) supplementation on circulating inflammatory cytokines among postmenopausal women with overweight or obesity and differing COMT genotypes. Methods: This study is a secondary analysis of a random subset (N = 97) from the Minnesota Green Tea Trial (MGTT), a randomized double-blinded placebo-controlled trial. The intervention was a high-dose GTE supplement (843 ± 44 mg EGCG/day) or placebo for 1 year. Serum CRP, TNF-α, and IL-6 were measured at 0, 6, and 12 months. Absolute changes in inflammatory cytokines from baseline to month 12 were evaluated using linear mixed-effects models adjusted for age, body mass index (BMI), smoking history, physical activity, and vitamin supplement use. Results: The changes from month 0 to month 12 were not statistically different between the groups for any of the inflammatory cytokines measured. The overall treatment effect was not statistically significant for CRP (p = 0.24), IL-6 (p = 0.59), TNF-α (p = 0.36), nor for the interaction between treatment group and time (all Ps > 0.40). There was no significant interaction between treatment group and COMT genotype for the stated markers. Conclusions: A high-dose GTE supplement consumed daily for one year did not significantly decrease inflammatory cytokines among postmenopausal women with overweight or obesity. The COMT genotype did not modify the effects of GTE supplementation on inflammatory cytokines. Future studies with a larger sample size among those at high risk of systemic inflammation are warranted. DOI: 10.3390/nu18010143 PMCID: PMC12787635 PMID: 41515260 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflicts of interest related to this work.

Anti-fatigue and antioxidative effects of amino acid (Leu, Gln, Cys)-EGCG complex via NRF2 and PGC-1α pathways: insights from cellular, animal, and pilot clinical studies.

5. Nutr Res Pract. 2025 Oct;19(5):664-681. doi: 10.4162/nrp.2025.19.5.664. Epub 2025 Apr 14. Anti-fatigue and antioxidative effects of amino acid (Leu, Gln, Cys)-EGCG complex via NRF2 and PGC-1α pathways: insights from cellular, animal, and pilot clinical studies. Kim SM(1)(2), Suh HJ(1)(2), Lee W(3), Kim B(3), Han SH(4)(5), Jung EY(6), Chang YB(1). Author information: (1)Department of Integrated Biomedical and Life Science, Graduate School, Korea University, Seoul 02841, Korea. (2)Transdisciplinary Major in Learning Health Systems, Graduate School, Korea University, Seoul 02841, Korea. (3)LingTea, Seoul 06611, Korea. (4)Institute of Human Behavior & Genetics, Korea University, Seoul 02841, Korea. (5)Biomedical Research Center, Anam Hospital, Korea University, Seoul 02841, Korea. (6)Department of Home Economic Education, Jeonju University, Jeonju 55069, R Korea. BACKGROUND/OBJECTIVES: Fatigue is closely associated with an impaired mitochondrial function, oxidative stress, and inefficient energy metabolism, all contributing to reduced physical performance. Nutritional strategies targeting mitochondrial biogenesis and antioxidant defense may help alleviate fatigue and enhance endurance. This study examined the anti-fatigue and antioxidant effects of an amino acid (AA)-epigallocatechin gallate (EGCG) mixture comprised of 3 AAs (cysteine [Cys], glutamine [Gln], and leucine [Leu]) and EGCG on mitochondrial biogenesis, oxidative stress mitigation, and physical performance enhancement. MATERIALS/METHODS: C2C12 myoblasts were treated to assess mitochondrial biogenesis-related gene expression and oxidative stress markers. Animal studies measured the swimming endurance, glycogen, adenosine triphosphate (ATP), and serum parameters. A pilot clinical trial evaluated the blood glucose, lactate, and serum enzyme levels post-exercise. RESULTS: In cellular experiments, a 1:1:3 ratio of the AA mixture (Cys, Gln, and Leu) with EGCG enhanced mitochondrial biogenesis-related gene expression (AMP-activated protein kinase, sirtuin 1, and peroxisome proliferator-activated receptor gamma coactivator 1α [PGC-1α]) and reduced the oxidative stress markers (reactive oxygen species and malondialdehyde [MDA]). Animal studies revealed significant increases in swimming endurance, elevated glycogen and ATP levels, and reduced serum fatigue markers (creatine phosphokinase, lactate dehydrogenase, and blood nitrogen). Furthermore, nuclear factor erythroid 2-related factor 2 (NRF2) and PGC-1α expression was significantly upregulated in the gastrocnemius muscle, supporting enhanced mitochondrial function. In addition, the antioxidant effects were observed with reduced MDA levels in liver tissue. Clinical trial data showed improved blood lactate clearance and higher post-exercise blood glucose levels in the AA-EGCG group compared to the placebo group. CONCLUSION: The AA-EGCG mixture enhances mitochondrial biogenesis and antioxidant capacity by activating the NRF2 and PGC-1α pathways, improving physical performance and reducing fatigue. This study highlights its potential as a supplement for managing fatigue and enhancing endurance. ©2025 The Korean Nutrition Society and the Korean Society of Community Nutrition. DOI: 10.4162/nrp.2025.19.5.664 PMCID: PMC12518752 PMID: 41098404 Conflict of interest statement: Conflict of Interest: The authors declare no potential conflicts of interests.

Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

6. Clin Ther. 2025 Oct;47(10):925-934. doi: 10.1016/j.clinthera.2025.07.015. Epub 2025 Aug 29. Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Saadh MJ(1), Gataa IS(2), Hussam AS(3), Kaur I(4), Kumar A(5), Godara P(6), Zainul R(7), Muzammil K(8), Zahrani Y(9). Author information: (1)Faculty of Pharmacy, Middle East University, Amman, 11831, Jordan. (2)Warith Al-Anbiyaa University, Karbala, 56001, Iraq. (3)Medical Laboratory Technique College, The Islamic University, Najaf, Iraq; Medical Laboratory Technique College, The Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq. (4)Department of Biotechnology and Genetics, Jain (Deemed-to-be) University, Bengaluru, Karnataka, 560069, India; Department of Allied Healthcare and Sciences, Vivekananda Global University, Jaipur, Rajasthan, 303012, India. (5)School of Pharmacy-Adarsh Vijendra Institute of Pharmaceutical Sciences, Arka Jain University, Jamshedpur, Jharkhand, 831001, India; Department of Pharmacy, Arka Jain University, Jamshedpur, Jharkhand, 831001, India. (6)Department of Nutrition and Dietetics, Chandigarh Pharmacy College, Chandigarh Group of Colleges, Jhanjheri, Mohali, 140307, Punjab, India. (7)Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Negeri Padang, Padang, Indonesia; Center for Advanced Material Processing, Artificial Intelligence, and Biophysics Informatics (CAMPBIOTICS), Universitas Negeri Padang, Padang, Indonesia; Researcher Fellow at Asia Pacific University of Technology and Innovations (APU), Malaysia. Electronic address: rahadianzmsiphd@fmipa.unp.ac.id. (8)Department of Public Health, College of Applied Medical Sciences, Khamis Mushait Campus, King Khalid University, Abha, 62561, Saudi Arabia. (9)Department of Public Health College of Applied Medical Sciences, Khamis Mushait, King Khalid University, Abha, , Saudi Arabia. PURPOSE: Epigallocatechin gallate (EGCG), a major catechin found in green tea, has been suggested to influence glycemic control. This systematic review and meta-analysis aim to evaluate the effects of EGCG on the glycemic index (GI) and related glycemic parameters. METHODS: Using predefined keywords, online databases (PubMed, Scopus, Web of Science Core Collection, and Google Scholar) were searched for relevant studies, published from inception up to May 2024. Initially 1994 studies were obtained out of which 41 RCTs were decided to be included for further analyses. FINDINGS: The meta-analysis demonstrated that EGCG supplementation led to statistically significant, but modest, reductions in fasting blood glucose (FBG), HbA1c, and HOMA-IR. Notably, the reduction in HbA1c (WMD: -0.18%, 95% CI: -0.35, -0.02; P = 0.029) was small and may not equate to clinically meaningful benefits for all populations. Furthermore, the effect on fasting insulin was not statistically significant (WMD: -0.50; 95% CI: -1.46, 0.47; P = 0.313), indicating a lack of robust or consistent impact on this parameter across studies. IMPLICATIONS: Although EGCG supplementation is associated with improvements in some glycemic parameters, these effects especially for HbA1c and fasting insulin are modest and may not be clinically meaningful for most population. Therefore, current evidence does not strongly support the use of EGCG as a stand-alone intervention for glycemic control. Copyright © 2025 Elsevier Inc. All rights reserved. DOI: 10.1016/j.clinthera.2025.07.015 PMID: 40885603 [Indexed for MEDLINE] Conflict of interest statement: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Impact of Dietary Supplements on Clinical Outcomes and Quality of Life in Patients with Breast Cancer: A Systematic Review.

7. Nutrients. 2025 Mar 11;17(6):981. doi: 10.3390/nu17060981. Impact of Dietary Supplements on Clinical Outcomes and Quality of Life in Patients with Breast Cancer: A Systematic Review. Scafuri L(1)(2), Buonerba C(1)(2), Strianese O(1), de Azambuja E(3), Palleschi M(4), Riccio V(5), Marotta V(6), Scocca C(7), Riccio G(8), Errico C(9), Arpino G(10), Di Lorenzo G(1)(2)(11). Author information: (1)Oncology Unit, "Andrea Tortora" Hospital, ASL Salerno, 84016 Pagani, Italy. (2)Associazione O.R.A. ETS-Oncology Research Assistance, 84134 Salerno, Italy. (3)Institut Jules Bordet, l'Université Libre de Bruxelles, 1070 Brussels, Belgium. (4)Medical Oncology, Breast & GYN Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy. (5)Ospedale SS Maria della Pietà, 80026 Casoria, Italy. (6)UOC Clinic of Endocrinology and Diabetology, AOU San Giovanni di Dio and Ruggi d'Aragona, 84131 Salerno, Italy. (7)Lincolnshire Pain Service Connect Health, Newcastle Upon Tyne NE12 8EU, UK. (8)Department of Medicine, University "Luigi Vanvitelli" of Naples, 80138 Naples, Italy. (9)A.O.U. Vanvitelli, Internal Medicine-San Paolo Hospital Campus (Fuorigrotta), 80142 Naples, Italy. (10)Department of Clinical Medicine and Surgery, University of Naples Federico II, 80133 Naples, Italy. (11)Department of Medicine, UniCamillus-Saint Camillus International University of Health Sciences, 00131 Rome, Italy. Background: This systematic review aimed to evaluate the efficacy and safety of dietary supplements in breast cancer patients, focusing on their impact on clinical outcomes, treatment-related side effects, and therapy adherence. Methods: Only RCTs investigating the effects of various orally administered supplements in adult breast cancer patients were included. Well-defined substances like vitamins, minerals, antioxidants, and specific herbal extracts were explored. The review excluded studies solely based on dietary interventions or non-supplemental approaches. The primary outcome assessed was quality of life. Secondary outcomes included disease-free survival, overall survival, tumor response, and biomarkers indicative of disease progression. Results: A total of 45 randomized controlled trials (RCTs) were included in this systematic review. Overall, supplementation was not associated with serious adverse events in the included trials. Vitamin D supplementation showed promise in some studies, with potential immunomodulatory and antioxidant effects, particularly when combined with other interventions. Omega-3 fatty acids and beta-glucan demonstrated potential in alleviating certain symptoms and improving quality of life. Studies on amino acids like acetyl-L-carnitine and L-arginine also yielded mixed results. Beta-glucan exhibited potential for immune-enhancing effects, while melatonin and creatine showed limited or no benefit for fatigue or muscle strength. Herbal extracts, including silymarin, curcumin, and EGCG, had varied effects. Curcumin studies presented mixed results. Silymarin showed potential for hepatoprotective effects. Conclusions: These findings highlight the potential of specific dietary supplements to improve various aspects of breast cancer care. However, the evidence is mixed across supplement types, and further research is needed to determine the most effective and safe approaches. DOI: 10.3390/nu17060981 PMCID: PMC11945011 PMID: 40290044 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflict of interest.

Prospective Comparative Study of an Oral Synbiotic and a Myoinositol-Based Herbal Supplement in Modifying Hormone Levels and the Gut Microbiome in Non-cystic Acne.

8. Dermatol Ther (Heidelb). 2025 Jun;15(6):1331-1350. doi: 10.1007/s13555-025-01411-4. Epub 2025 Apr 18. Prospective Comparative Study of an Oral Synbiotic and a Myoinositol-Based Herbal Supplement in Modifying Hormone Levels and the Gut Microbiome in Non-cystic Acne. Min M(1)(2)(3), Afzal N(1)(2), Maloh J(4), Dulai AS(1)(2), Ahmad N(1)(2)(5), Pinzauti D(6), Sivamani RK(7)(8)(9)(10)(11). Author information: (1)Integrative Skin Science and Research, Sacramento, CA, USA. (2)Integrative Research Institute, Sacramento, CA, USA. (3)College of Medicine, California Northstate University, Elk Grove, CA, USA. (4)Codex Labs Corp, San Jose, CA, 95124, USA. (5)College of Medicine, University of Houston, Houston, TX, USA. (6)The Bio Arte Limited, Laboratories at Life Science Park, Triq San Giljan, San Gwann, Malta. (7)Integrative Skin Science and Research, Sacramento, CA, USA. raja.sivamani.md@gmail.com. (8)Integrative Research Institute, Sacramento, CA, USA. raja.sivamani.md@gmail.com. (9)College of Medicine, California Northstate University, Elk Grove, CA, USA. raja.sivamani.md@gmail.com. (10)Department of Dermatology, University of California-Davis, Sacramento, CA, USA. raja.sivamani.md@gmail.com. (11)Pacific Skin Institute, Sacramento, CA, USA. raja.sivamani.md@gmail.com. INTRODUCTION: Acne pathogenesis is multifactorial, involving systemic factors including gut dysbiosis, hormones, and chronic inflammation. Probiotics, myoinositol, and plant-derived molecules may modulate acne by targeting these factors. The objective is to compare a synbiotic containing herbs against a myoinositol-based herbal supplement on how they influence acne, the gut microbiome, short chain fatty acids (SCFAs), and hormonal profiles. METHODS: This was an 8-week, randomized study involving 36 male and female patients aged 12 to 45 years with non-cystic acne. Subjects received either a synbiotic or a myoinositol-based herbal supplement (MBHS). Acne lesions were counted, stool samples were collected for gut microbiome and SCFA analyses, and hormone collections were performed at baseline, 4, and 8 weeks. RESULTS: Several gut bacteria increased by at least threefold at both week 4 and 8 in the synbiotic (Erysipelatoclostridium merdavium, Blautia argi, Faecalibacterium prausnitzii, Prevotella copri, Streptococcus sp001556435, Blautia sp900541955) and MBHS group (Megamonas funiformis, Ligilactobacillus ruminis, Prevotella ssp015074785, Prevotella copri, Gca-900199835 sp900176495). Acne lesion counts decreased significantly in both groups at week 4 (p < 0.0001) and week 8 (synbiotic, p < 0.0001; MBHS, p < 0.0001). There were significant and trending increases in stool and plasma SCFAs in both cohorts at week 4 and 8. After 8 weeks of MBHS, 17-OHP and androstenedione significantly decreased from 27.3 to 11.3 pg/ml (p = 0.001) and 94.9 to 68.0 pg/ml (p = 0.04), respectively. CONCLUSION: Both the synbiotic and MBHS improved gut health, augmented SCFAs, and reduced lesion counts in those with non-cystic acne. The MBHS may act by reducing hormone levels of 17-OHP and androstenedione. CLINICAL TRIAL REGISTRATION: www. CLINICALTRIALS: gov (NCT05919810). © 2025. The Author(s). DOI: 10.1007/s13555-025-01411-4 PMCID: PMC12092896 PMID: 40246799 Conflict of interest statement: Declarations. Conflict of Interest: Jessica Maloh serves as a consultant and stockholder for Codex Labs. Raja K. Sivamani serves as a scientific advisor and a holder of stock options with Codex Labs, a scientific advisor to Arbonne, and as a consultant to Burt’s Bees, Novozymes, Nutrafol, Abbvie, Leo, Galderma, Pfizer, UCB, Incyte, Sanofi, Novartis, Arcutis, Amgen, Sun and Regeneron Pharmaceuticals. Mildred Min, Nasima Afzal, Ajay Dulai, Nabeel Ahmad, and David Pinzauti report no conflict of interest. Ethics Approval: The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Allendale Institutional Review Board (CB_Acne_Supp) on June 26, 2023. Written informed consent and assent (where appropriate) was obtained from all subjects and/or guardians involved in the study.

Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene.

9. Clin Transl Sci. 2025 Mar;18(3):e70189. doi: 10.1111/cts.70189. Evaluating the Effect of Epigallocatechin Gallate (EGCG) in Reducing Folate Levels in Reproductive Aged Women by MTHFR and DHFR Genotype in Combination With Letrozole or Clomiphene. Johnson JJ(1), Siblini H(2), Al-Hendy A(2), Segars JH(3), González F(4), Taylor HS(5), Singh B(3), Carson SA(5), Christman GM(6), Huang H(7), Dangi B(1), Zhang H(7). Author information: (1)Department of Pharmacy Practice, University of Illinois Chicago, Chicago, Illinois, USA. (2)Department of Obstetrics and Gynecology, University of Chicago, Chicago, Illinois, USA. (3)Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. (4)Department of Obstetrics and Gynecology, University of Illinois Chicago, Chicago, Illinois, USA. (5)Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale University, New Haven, Connecticut, USA. (6)Center for Reproductive Medicine, University of Michigan Health, Ann Arbor, Michigan, USA. (7)Department of Biostatistics, Yale University School of Public Health, New Haven, Connecticut, USA. Previous epidemiological studies have suggested that green tea catechins, including Epigallocatechin-3-gallate (EGCG), the most abundant polyphenol in green tea, may be associated with reduced serum folate levels. This is of particular interest as women of childbearing age may be consuming EGCG from tea, dietary supplements, or involved in active clinical trials studying EGCG or green tea extract. EGCG was reported to shrink uterine fibroids in preclinical and clinical studies. This observation led to the development of a multicenter NICHD-funded clinical trial to evaluate the safety of EGCG for treating women with fibroids and unexplained infertility (NCT04177693). To answer the question of whether green tea extract standardized to EGCG led to a reduction in folate, 39 women aged ≥ 18 to ≤ 40 years, with/without uterine fibroids, were evaluated. These women were randomized to receive either EGCG, EGCG + clomiphene, or EGCG + letrozole for 30 days. A daily dose of 720 mg of highly characterized green tea extract containing EGCG was used. Participants were genotyped for polymorphisms at positions 677 and 1298 in MTHFR and for the -19 bp deletion polymorphism of DHFR. During the intervention with EGCG, folate levels remained in the normal range in all subjects. Our data suggest that in reproductive-age women, a 30-day course of EGCG 720 mg daily taken alone or in combination with clomiphene citrate or letrozole (for 5 days) is well-tolerated and is not associated with folate deficiency even in the presence of MTHFR and/or DHFR polymorphisms known to negatively impact folate synthesis. Trial Registration: Clinical trial: NCT01311869. © 2025 The Author(s). Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. DOI: 10.1111/cts.70189 PMCID: PMC11903501 PMID: 40077973 [Indexed for MEDLINE] Conflict of interest statement: A.A.‐H. is serving as a consultant for OBS‐EVA, Myovant, Pfizer, Bayer, and previously for AbbVie, Novartis, and Crila. J.J.J. is serving as a consultant for Wholesome Nutritionals. The other authors declare no conflicts of interest.

Polyphenols for the Prevention or Management of Preeclampsia: A Systematic Review and Meta-Analysis.

10. BJOG. 2025 Jun;132(7):867-879. doi: 10.1111/1471-0528.18106. Epub 2025 Mar 3. Polyphenols for the Prevention or Management of Preeclampsia: A Systematic Review and Meta-Analysis. Nguyen PY(1), Sanderson B(1), Makama M(1), Mills K(1), Ammerdorffer A(2), Gülmezoglu AM(2), Vogel JP(1), McDougall ARA(1). Author information: (1)Maternal, Child and Adolescent Health Program, Burnet Institute, Melbourne, Australia. (2)Concept Foundation, Geneva, Switzerland. OBJECTIVES: To evaluate the effects of polyphenol-containing products during pregnancy on preeclampsia-related maternal and neonatal outcomes. DESIGN: Systematic review and meta-analysis. SETTING: Nine databases and one trial registry, from inception to August 11th, 2023. POPULATION/SAMPLE: Randomised controlled trials where women received polyphenolic-containing products (as standardised extracts or dietary supplements) compared to placebo or standard care. METHODS: All review stages were conducted by two independent reviewers. Random-effects meta-analysis with the Hartung-Knapp-Sidik-Jonkman method using a framework for studies with few events. MAIN OUTCOME MEASURES: Clinical outcomes combining the core outcome set for preeclampsia and WHO's priority outcomes. RESULTS: Fourteen trials investigating six candidates were included. In women with preeclampsia, the addition of epigallocatechin gallate (EGCG) to nifedipine may reduce the time needed to achieve blood pressure control (mean difference (MD) = -14.10 min, 95% CI -18.46 to -9.74) and increase the time to the next hypertensive crisis (MD = 3.10 h, 95% CI 2.35 to 3.85) compared to nifedipine alone (1 trial, 349 women; low certainty). Similarly, the addition of resveratrol to nifedipine may reduce the time needed to achieve blood pressure control (MD = -15.50 min, 95% CI -19.83 to -11.17) and increase the time to the next hypertensive crisis (MD = 2.50 h, 95% CI 2.09 to 2.91) (1 trial, 349 women; low certainty). No differences were observed for other outcomes or candidates (Salvia miltiorrhiza, Bryophyllum pinnatum , raspberry and cranberry extracts). CONCLUSIONS: ECGC and resveratrol supplements have been investigated for potential effects in managing clinical signs and symptoms of preeclampsia; however, evidence on the clinical and adverse effects of polyphenols is limited and uncertain. © 2025 The Author(s). BJOG: An International Journal of Obstetrics and Gynaecology published by John Wiley & Sons Ltd. DOI: 10.1111/1471-0528.18106 PMCID: PMC12051244 PMID: 40025969 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflicts of interest.

The Effects of Epigallocatechin-3-Gallate Nutritional Supplementation in the Management of Multiple Sclerosis: A Systematic Review of Clinical Trials.

11. Nutrients. 2024 Aug 15;16(16):2723. doi: 10.3390/nu16162723. The Effects of Epigallocatechin-3-Gallate Nutritional Supplementation in the Management of Multiple Sclerosis: A Systematic Review of Clinical Trials. Schuldesz AC(1), Tudor R(2), Nandarge PS(3), Elagez A(4), Cornea A(2), Ion R(5), Bratosin F(6), Prodan M(1), Simu M(2). Author information: (1)Doctoral School, "Victor Babes" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania. (2)Discipline of Neurology, "Victor Babes" University of Medicine and Pharmacy Timisoara, 300041 Timisoara, Romania. (3)Department of General Medicine, D.Y. Patil Medical College Kolhapur, Kolhapur 416005, India. (4)Department of General Medicine, Misr University for Science & Technology, Giza 3236101, Egypt. (5)Department III Functional Sciences, Division of Public Health and Management, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania. (6)Methodological and Infectious Diseases Research Center, Department of Infectious Diseases, Victor Babes University of Medicine and Pharmacy, 300041 Timisoara, Romania. Multiple sclerosis (MS) is a chronic, debilitating neurological condition for which current treatments often focus on managing symptoms without curing the underlying disease. Recent studies have suggested that dietary supplements could potentially modify disease progression and enhance quality of life. This systematic review aims to evaluate the efficacy and safety of epigallocatechin-3-gallate (EGCG) as a dietary supplement in patients with MS, with a specific focus on its impact on disease progression, symptom management, and overall quality of life. We conducted a comprehensive systematic review following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, utilizing an exhaustive search across the databases PubMed, Scopus, and Web of Science up to 23 February 2024. Eligible studies were randomized controlled trials. Nine clinical trials involving 318 participants were analyzed, with dosages ranging from 600 mg to 1200 mg of EGCG daily, although most studies had only a 4-month follow-up period. Results indicated that EGCG supplementation, particularly when combined with coconut oil, led to significant improvements in metabolic health markers and functional abilities such as gait speed and balance. One trial observed significant improvements in the Berg balance scale score from an average of 49 to 52 after four months of treatment with 800 mg of EGCG daily. Additionally, interleukin-6 levels significantly decreased, suggesting anti-inflammatory effects. Measures of quality of life such as the Beck Depression Inventory (BDI) scale showed significant improvements after EGCG supplementation. However, primary outcomes like disease progression measured by the Expanded Disability Status Scale (EDSS) and Magnetic Resonance Imaging (MRI) of lesion activities showed minimal or no significant changes across most studies. EGCG supplementation appears to provide certain symptomatic and functional benefits in MS patients, particularly in terms of metabolic health and physical functionality. However, it does not significantly impact the primary disease progression markers such as EDSS scores and MRI lesions. These findings underscore the potential of EGCG as a supportive treatment in MS management, though its role in altering disease progression remains unclear. Future research should focus on long-term effects and optimal dosing to further elucidate its therapeutic potential. DOI: 10.3390/nu16162723 PMCID: PMC11356828 PMID: 39203859 [Indexed for MEDLINE] Conflict of interest statement: The authors declare no conflicts of interest.

Examination of sex-specific interactions between gut microbiota and host metabolism after 12-week combined polyphenol supplementation in individuals with overweight or obesity.

12. Gut Microbes. 2024 Jan-Dec;16(1):2392875. doi: 10.1080/19490976.2024.2392875. Epub 2024 Aug 25. Examination of sex-specific interactions between gut microbiota and host metabolism after 12-week combined polyphenol supplementation in individuals with overweight or obesity. Jardon KM(1)(2), Goossens GH(1), Most J(1)(3), Galazzo G(4), Venema K(5), Penders J(4), Blaak EE(1)(2). Author information: (1)Department of Human Biology, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands. (2)TiFN, Wageningen, The Netherlands. (3)Department of Orthopedics, Zuyderland Medical Center, Sittard-Geleen, The Netherlands. (4)Department of Medical Microbiology, Infectious Diseases and Infection Prevention, NUTRIM School of Nutrition and Translational Research in Metabolism, Maastricht University Medical Centre+, Maastricht, The Netherlands. (5)Centre for Healthy Eating & Food Innovation, Maastricht University Campus Venlo, Venlo, The Netherlands. Polyphenols exert beneficial effects on host metabolism, which may be mediated by the gut microbiota. We investigated sex-specific differences in microbiota composition and interactions with cardiometabolic parameters after polyphenol supplementation in individuals with overweight/obesity. In a double-blind, randomized, placebo-controlled trial, 19 women and 18 men with normal glucose tolerance and body mass index >25 kg/m2 received epigallocatechin-3-gallate and resveratrol (EGCG+RES, 282 + 80 mg/d) or placebo supplements for 12 weeks. Fecal microbiota composition (16S rRNA gene amplicon sequencing, V3-V4 region), in vivo whole-body fat oxidation (indirect calorimetry), and mitochondrial respiration in permeabilized skeletal muscle fibers (SkM-Ox; ex vivo respirometry) were determined pre- and post-intervention. Overall, EGCG+RES supplementation did not affect gut microbiota composition. Akkermansia, Ruminococcaceae UCG-002, Subdoligranulum, and Lachnospiraceae UCG-004 were more abundant, while Veillonella, Tyzzerella 4, Clostridium innocuum group, Ruminococcus gnavus group, Escherichia-Shigella, and an uncultured Ruminococcaceae family genus were less abundant in women compared to men. In women, only baseline Eubacterium ventriosum group abundance correlated with EGCG+RES-induced changes in SkM-Ox. In men, low Dorea, Barnsiella, Anaerotruncus, Ruminococcus, Subdoligranulum, Coprococcus, Eubacterium ventriosum group, Ruminococcaceae UCG-003, and a Ruminococcaceae family genus abundance, and high Blautia abundance at baseline were associated with improvements in SkM-Ox. Changes in whole-body fat oxidation were not associated with gut microbiota features. We conclude that baseline microbiota composition predicts changes in SkM-Ox as a result of EGCG+RES supplementation in men but not in women. Men may be more prone to diet-induced, gut microbiota-related improvements in cardiometabolic health. These sex-differences should be further investigated in future precision-based intervention studies. DOI: 10.1080/19490976.2024.2392875 PMCID: PMC11346568 PMID: 39182247 [Indexed for MEDLINE] Conflict of interest statement: No potential conflict of interest was reported by the author(s).

Promising Roles of Phytocompounds and Nutrients in Interventions to Mitigate Chemotherapy-Induced Peripheral Neuropathy.

13. Semin Oncol Nurs. 2024 Oct;40(5):151713. doi: 10.1016/j.soncn.2024.151713. Epub 2024 Aug 14. Promising Roles of Phytocompounds and Nutrients in Interventions to Mitigate Chemotherapy-Induced Peripheral Neuropathy. Daniel M(1), Smith EL(2). Author information: (1)School of Nursing, University of Alabama, Birmingham, Alabama, USA. (2)School of Nursing, University of Alabama, Birmingham, Alabama, USA. Electronic address: esmith3@uab.edu. OBJECTIVES: Provide an overview of scientific reports and literature related to the role(s) of phytocompounds and nutrients in neuroprotection. Discuss how these properties may inform nutrition- and dietary interventions to mitigate chemotherapy-induced peripheral neuropathy (CIPN), for which there are no effective treatments. METHODS: A literature search (2010-2023) was conducted in PubMed and Google Scholar where search terms-diet, nutrition, neuroprotection, neurodegenerative diseases, and social determinants of health-were used to narrow articles. From this search, manuscripts were reviewed to provide an overview of the neuroprotective properties of various phytocompounds and nutrients and their observed effects in neurodegenerative conditions and CIPN. Social determinant of health factors (SDOH) related to economic stability and access to nutritious foods were also reviewed as potential barriers to dietary interventions. RESULTS: Twenty-eight publications were included in this literature review. Phytocompounds found in green tea (EGCG), turmeric (curcumin), cruciferous vegetables (sulforaphane), as well as certain vitamins, are promising, targeted interventions to mitigate CIPN. SDOH factors such as economic instability and limited access to nutritious foods may act as barriers to dietary interventions and limit their generalizability. CONCLUSION: Dietary interventions focused on the use of phytocompounds and vitamins with known antioxidant, anti-inflammatory, and neuroprotective properties, hold promise and may provide patients with natural, non-pharmacological therapeutics for the management and/or prevention of CIPN. However, rigorous clinical trial research is needed to explore these effects in humans. IMPLICATIONS FOR NURSING PRACTICE: Nurses support cancer survivors at the point-of-care, particularly during and after neurotoxic chemotherapy treatments. If future research supports dietary interventions to mitigate CIPN, nurses will ultimately be positioned to help translate this knowledge into clinical practice through educating patients on how to infuse nutrient-rich foods into their diets. Further, nurses will need to be conscious of SDOH factors that may impede access to these foods. Copyright © 2024 Elsevier Inc. All rights reserved. DOI: 10.1016/j.soncn.2024.151713 PMID: 39147680 [Indexed for MEDLINE] Conflict of interest statement: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Ellen M. Lavoie Smith reports administrative support was provided by The University of Alabama at Birmingham School of Nursing. Ellen M. Lavoie Smith reports a relationship with University of Alabama at Birmingham that includes employment. Ellen Lavoie Smith, PhD, MSN, RN, FAAN was a Guest Editor for the “Neurotoxicity in Survivorship” Special Issues of Seminars in Oncology Nursing. As co-author of this paper, Dr. Smith participated in editorial process and decision-making regarding its content. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Metabolomics strategy comprehensively unveils the effect of catechins intervention on the biomarkers of exposure to acrylamide and biomarkers of cardiometabolic risk.

14. Environ Int. 2022 Nov;169:107517. doi: 10.1016/j.envint.2022.107517. Epub 2022 Sep 12. Metabolomics strategy comprehensively unveils the effect of catechins intervention on the biomarkers of exposure to acrylamide and biomarkers of cardiometabolic risk. Wan X(1), Jia W(1), Wang Q(2), Chen X(2), Wang A(1), Zhu L(1), Liu X(3), Zhang L(3), Zhuang P(1), Jiao J(3), Zhang Y(4). Author information: (1)Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang, China; National Engineering Laboratory of Intelligent Food Technology and Equipment, Zhejiang Key Laboratory for Agro-Food Processing, College of Biosystems Engineering and Food Science, Zhejiang University, Hangzhou 310058, Zhejiang, China. (2)National Engineering Laboratory of Intelligent Food Technology and Equipment, Zhejiang Key Laboratory for Agro-Food Processing, College of Biosystems Engineering and Food Science, Zhejiang University, Hangzhou 310058, Zhejiang, China. (3)Department of Nutrition, School of Public Health, Department of Clinical Nutrition, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310058, Zhejiang, China. (4)Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang, China; National Engineering Laboratory of Intelligent Food Technology and Equipment, Zhejiang Key Laboratory for Agro-Food Processing, College of Biosystems Engineering and Food Science, Zhejiang University, Hangzhou 310058, Zhejiang, China. Electronic address: y_zhang@zju.edu.cn. Polyphenolic antioxidants have been suggested to control the generation of acrylamide during thermal reactions. However, their role in protecting against the toxicity of acrylamide and the mechanism of action regarding profile alteration of biomarkers and metabolome remains unclear. A total of 65 adults were randomized into tea polyphenols (TP) and control groups and served with potato chips, which corresponded to an intake level of 12.6 μg/kg·bw of acrylamide, followed by capsules containing 200 mg, 100 mg or 50 mg TP, or equivalent placebo. Moreover, nontargeted urinary metabolomics analysis in acrylamide exposed rats was conducted using ultra-high performance liquid chromatography linked with a quadrupole-orbitrap high-resolution mass spectrometry. Our results showed that supplementation with catechins promoted the excretion of N-acetyl-S-(2-carbamoyl-2-hydroxyethyl)-l-cysteine in both humans and rats. We also found that epigallocatechin gallate (EGCG) or epicatechin (EC) intervention attenuated the ratio of hemoglobin adduct of glycidamide to hemoglobin adduct of acrylamide in rat blood. Metabolomics analysis revealed that EGCG/EC intervention regulated the differential expressed metabolites, including l-glutamic acid, 2-oxoglutarate, citric acid, and cysteinylglycine. Kyoto Encyclopedia of Genes and Genomes pathway analysis further showed acrylamide-induced metabolic disorders were improved after EGCG/EC supplementation by glycolipid metabolism (alanine, aspartate and glutamate metabolism, and d-Glutamine and d-glutamate metabolism) and energy metabolism (tricarboxylic acid cycle). Notably, the supplement use of EGCG prevented the cardiometabolic risk after exposure to acrylamide by mediating the phenylalanine and hippuric acid in phenylalanine metabolism. Here we showed the beneficial effect of catechins as major polyphenolic antioxidant ingredients on the toxicity of acrylamide by the changes in biomarkers from metabolic profile analysis based on human and animal studies. These findings shed light into the catechins as natural polyphenolic antioxidants that could be a therapeutic ingredient for preventing acrylamide-induced cardiometabolic toxicity. Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved. DOI: 10.1016/j.envint.2022.107517 PMID: 36191485 [Indexed for MEDLINE] Conflict of interest statement: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Hepatotoxicity with High-Dose Green Tea Extract: Effect of Catechol-O-Methyltransferase and Uridine 5'-Diphospho-glucuronosyltransferase 1A4 Genotypes.

15. J Diet Suppl. 2023;20(6):850-869. doi: 10.1080/19390211.2022.2128501. Epub 2022 Sep 30. Hepatotoxicity with High-Dose Green Tea Extract: Effect of Catechol-O-Methyltransferase and Uridine 5'-Diphospho-glucuronosyltransferase 1A4 Genotypes. Acosta L(1), Byham-Gray L(1), Kurzer M(2), Samavat H(1). Author information: (1)Department of Clinical and Preventive Nutrition Sciences, Rutgers University School of Health Professions, Newark, NJ, USA. (2)Department of Food Science and Nutrition, University of Minnesota, St. Paul, MN, USA. The predominant catechin in green tea, epigallocatechin gallate (EGCG), may be hepatotoxic in high doses. Our objective was to investigate the influence of catechol-O-methyltransferase (COMT) and uridine 5'-diphospho-glucuronosyltransferase 1A4 (UGT1A4) genotypes on changes in liver injury biomarkers in response to long-term, high-dose green tea extract (GTE) supplementation among postmenopausal women. A secondary analysis was conducted using data from the Minnesota Green Tea Trial (N = 1,075), in which participants were randomized to consume high-dose GTE (843 mg/day EGCG) or placebo capsules for 12 months. Analysis of covariance adjusting for potential confounders was performed to examine changes in aspartate aminotransferase (AST), alanine aminotransferase (ALT), AST: ALT ratio, and alkaline phosphatase from baseline to months 3, 6, 9, and 12 across COMT and UGT1A4 genotypes. Mean age and BMI within the GTE group (n = 400) were 59.8 yrs and 25.1 kg/m2, respectively, and 98% of subjects were white. From baseline to month 3, mean AST: ALT ratio change was +1.0% in the COMT (rs4680) A/G genotype versus -4.8% in the A/A genotype (p = 0.03). From baseline to months 6 and 9, respectively, mean ALT change was +78.1% and +82.1% in the UGT1A4 (rs6755571) A/C genotype versus +28.0% and +30.1% in the C/C genotype (p < 0.001 and p = 0.004, respectively). The UGT1A4 (rs6755571) A/C genotype may be an important risk factor for clinically-relevant serum transaminase elevations with 6-9 months of high-dose GTE supplementation among postmenopausal women. Understanding the genetic underpinnings of GTE-related hepatotoxicity may allow for a genetically-informed paradigm for therapeutic use of GTE. DOI: 10.1080/19390211.2022.2128501 PMCID: PMC10060436 PMID: 36178169 [Indexed for MEDLINE] Conflict of interest statement: Declaration of Interest: The authors disclose no conflicts of interest.